A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227703
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
391
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Emraclidine 15 mg
DRUG:
Emraclidine 30 mg
DRUG:
Placebo
Sponsor
AbbVie